Candriam Luxembourg S.C.A. boosted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 25.4% in the third quarter, according to its most recent filing with the SEC. The firm owned 89,000 shares of the specialty pharmaceutical company’s stock after acquiring an additional 18,000 shares during the period. Candriam Luxembourg S.C.A. owned 0.18% of Supernus Pharmaceuticals worth $3,560,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in Supernus Pharmaceuticals by 0.5% during the 2nd quarter. BlackRock Inc. now owns 6,727,641 shares of the specialty pharmaceutical company’s stock worth $289,962,000 after acquiring an additional 31,331 shares during the period. Vanguard Group Inc. grew its holdings in Supernus Pharmaceuticals by 39.1% during the 2nd quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock worth $150,873,000 after acquiring an additional 984,200 shares during the period. State Street Corp grew its holdings in Supernus Pharmaceuticals by 3.1% during the 2nd quarter. State Street Corp now owns 1,397,484 shares of the specialty pharmaceutical company’s stock worth $60,230,000 after acquiring an additional 42,165 shares during the period. Rice Hall James & Associates LLC grew its holdings in Supernus Pharmaceuticals by 24.5% during the 2nd quarter. Rice Hall James & Associates LLC now owns 1,361,373 shares of the specialty pharmaceutical company’s stock worth $58,675,000 after acquiring an additional 267,971 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in Supernus Pharmaceuticals by 10.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,268,082 shares of the specialty pharmaceutical company’s stock worth $54,654,000 after acquiring an additional 122,042 shares during the period. 96.45% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Candriam Luxembourg S.C.A. Has $3.56 Million Holdings in Supernus Pharmaceuticals, Inc. (SUPN)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/11/15/candriam-luxembourg-s-c-a-has-3-56-million-holdings-in-supernus-pharmaceuticals-inc-supn.html.

Several brokerages have recently issued reports on SUPN. Piper Jaffray Companies reissued a “hold” rating and issued a $41.00 price target on shares of Supernus Pharmaceuticals in a report on Tuesday, September 26th. Cantor Fitzgerald reissued a “buy” rating and issued a $49.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, September 27th. Stifel Nicolaus reissued a “buy” rating and issued a $47.00 price target (up previously from $36.00) on shares of Supernus Pharmaceuticals in a report on Tuesday, July 18th. BidaskClub raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Finally, FBR & Co began coverage on shares of Supernus Pharmaceuticals in a report on Thursday, October 19th. They issued a “buy” rating and a $53.00 price target for the company. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $49.60.

Shares of Supernus Pharmaceuticals, Inc. (SUPN) opened at $36.85 on Wednesday. The company has a market cap of $1,937.71, a price-to-earnings ratio of 35.66, a P/E/G ratio of 1.60 and a beta of 1.30. Supernus Pharmaceuticals, Inc. has a 52-week low of $20.55 and a 52-week high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.27 by $0.02. The business had revenue of $80.40 million for the quarter, compared to analysts’ expectations of $78.74 million. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The firm’s quarterly revenue was up 41.5% compared to the same quarter last year. equities analysts predict that Supernus Pharmaceuticals, Inc. will post 1.07 EPS for the current year.

In related news, insider Stefan K.F. Schwabe sold 95,000 shares of the business’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $46.59, for a total value of $4,426,050.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Gregory S. Patrick sold 50,000 shares of the business’s stock in a transaction on Friday, September 8th. The shares were sold at an average price of $47.60, for a total transaction of $2,380,000.00. The disclosure for this sale can be found here. Insiders sold a total of 150,000 shares of company stock worth $7,055,350 over the last ninety days. 6.70% of the stock is currently owned by insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.